Clarity Pharmaceuticals (ASX:CU6) Other Long-Term Liabilities: A$0.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
30 GF Score
Price A$2.68
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Other Long-Term Liabilities?

Clarity Pharmaceuticals ASX:CU6 -0.74% 30 Other Long-Term Liabilities is A$0.55 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.55 Mil.

Clarity Pharmaceuticals's quarterly other long-term liabilities declined from Dec. 2024 (A$0.33 Mil) to Jun. 2025 (A$-0.00 Mil) but then increased from Jun. 2025 (A$-0.00 Mil) to Dec. 2025 (A$0.55 Mil).

Clarity Pharmaceuticals's annual other long-term liabilities increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then declined from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$-0.00 Mil).

Clarity Pharmaceuticals Other Long-Term Liabilities Related Terms

Clarity Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Other Long-Term Liabilities Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
-0.00 0.00 0.00 -0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.00 0.33 -0.00 0.55
ASX:CU6
30GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.55 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Other Long-Term Liabilities of A$0.55 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Other Long-Term Liabilities too high?
Clarity Pharmaceuticals' current Other Long-Term Liabilities is A$0.55 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Other Long-Term Liabilities compare to VRTX and REGN?
Clarity Pharmaceuticals' Other Long-Term Liabilities of A$0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Other Long-Term Liabilities is A$0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Other Long-Term Liabilities of A$0.55 Mil. The current Other Long-Term Liabilities is A$0.55 Mil. Clarity Pharmaceuticals' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Other Long-Term Liabilities is A$0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
30GF Score

Get the complete analysis for ASX:CU6

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.68
Price